BioStem Technologies, Inc.
BSEM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.85 | -0.18 | 0.03 |
| FCF Yield | 0.00% | 2.37% | 1.72% | 3.53% |
| EV / EBITDA | 35.89 | 1,080.43 | 38.55 | 24.41 |
| Quality | ||||
| ROIC | 1.41% | -0.69% | 8.60% | 34.33% |
| Gross Margin | 87.95% | 98.61% | 98.82% | 96.51% |
| Cash Conversion Ratio | -9.61 | 0.91 | 0.53 | 1.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 239.00% | 340.96% | 314.37% | 252.77% |
| Free Cash Flow Growth | 0.00% | 30.21% | -51.31% | -14.00% |
| Safety | ||||
| Net Debt / EBITDA | -15.57 | -157.09 | -4.22 | -2.14 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 129.00 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.28 | 0.43 | 1.97 |
| Cash Conversion Cycle | 40.37 | -138.92 | -82.75 | 6.08 |